Related references
Note: Only part of the references are listed.Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence
Deepak Cyril D'Souza et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Dopamine-Glutamate Interactions: A Neural Convergence Mechanism of Common Schizophrenia Risk Variants
Heike Tost et al.
BIOLOGICAL PSYCHIATRY (2011)
A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia
Robert W. Buchanan et al.
BIOLOGICAL PSYCHIATRY (2011)
A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
Bruce J. Kinon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Exome sequencing supports a de novo mutational paradigm for schizophrenia
Bin Xu et al.
NATURE GENETICS (2011)
Glutamatergic (N-Methyl-D-aspartate Receptor) Hypofrontality in Schizophrenia: Too Little Juice or a Miswired Brain?
Gerard J. Marek et al.
MOLECULAR PHARMACOLOGY (2010)
Testing the glutamate hypothesis of schizophrenia
Joshua A. Gordon
NATURE NEUROSCIENCE (2010)
Lamotrigine as add-on therapy in schizophrenia - Results of 2 placebo-controlled trials
Donald C. Goff et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2007)
NMDA receptor hypofunction produces opposite effects on prefrontal cortex Interneurons and pyramidal neurons
Houman Homayoun et al.
JOURNAL OF NEUROSCIENCE (2007)
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T. Patil et al.
NATURE MEDICINE (2007)
Cognitive dysfunction in schizophrenia -: Convergence of γ-aminobutyric acid and glutamate alterations
David A. Lewis et al.
ARCHIVES OF NEUROLOGY (2006)
Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine - Implications for glutamatergic and dopaminergic model psychoses and cognitive function
JH Krystal et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects
JH Krystal et al.
PSYCHOPHARMACOLOGY (2005)
Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats
L Homayoun et al.
JOURNAL OF NEUROPHYSIOLOGY (2005)
Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia
B Moghaddam
PSYCHOPHARMACOLOGY (2004)
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex
ME Jackson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development
JH Krystal et al.
PSYCHOPHARMACOLOGY (2003)
Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents
GG Kinney et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Comment on Ketamine has equal affinity for NMDA receptors and the high-affinity state of the dopamine D2 receptor
JH Krystal et al.
BIOLOGICAL PSYCHIATRY (2001)
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine -: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
A Anand et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Share Paper
